1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Diltiazem |
| brand | String | Cardizem, Tiazac, Cartia XT, Dilacor XR, Taztia XT, Matzim LA |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Calcium_channel_blockers|Calcium channel blocker (non-dihydropyridine)]] • [[:Category:Antianginals|Antianginal]] • [[:Category:Antiarrhythmics|Antiarrhythmic (class IV)]] • [[:Category:Antihypertensives|Antihypertensive]] |
| mechanism | String | '"`UNIQ--vote-0000063C-QINU`"' Avoid in HFrEF (negative inotropy). CYP3A4 substrate AND moderate inhibitor — interacts substantially with statins (especially simvastatin), tacrolimus, cyclosporine, and many other CYP3A4 substrates'"`UNIQ--ref-0000063D-QINU`"'. |
| uses | String | '"`UNIQ--vote-0000063E-QINU`"', '"`UNIQ--vote-0000063F-QINU`"', '"`UNIQ--vote-00000640-QINU`"', '"`UNIQ--vote-00000641-QINU`"' |
| starting_dose | String | ER 180-240 mg PO once daily; IR 30 mg PO QID; IV 0.25 mg/kg over 2 min for acute rate control, then 5-15 mg/h infusion |
| preparations | String | IR 30, 60, 90, 120 mg tablets; multiple ER capsules and tablets 60-420 mg; IV 5 mg/mL |
| fda_max | String | ~480 mg/d (oral); IV per protocol |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral (IR • multiple ER formulations) • IV |
| onset | String | IV: 3-7 minutes (rate control); PO IR: 30-60 minutes; ER: hours |
| duration | String | IR: 4-8 hours; ER: 24 hours |
| halflife | String | 3-4.5 hours (IR); 5-7 hours (ER; effective duration 24 hours via formulation)'"`UNIQ--ref-00000642-QINU`"' |
| bioavailability | String | ~40% (oral; extensive first-pass via CYP3A4)'"`UNIQ--ref-00000643-QINU`"' |
| pregnancy | String | Limited data; labetalol/nifedipine generally preferred. Crosses placenta.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
